These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19260121)

  • 1. Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
    Verma D; Fava C; Kantarjian H; Cortes J
    Am J Hematol; 2009 Apr; 84(4):256-7. PubMed ID: 19260121
    [No Abstract]   [Full Text] [Related]  

  • 2. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
    Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
    Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T; Eide CA; Deininger MW
    Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
    Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
    Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
    Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF
    Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
    Inokuchi K; Yamaguchi H; Tamai H; Dan K
    J Clin Exp Hematop; 2012; 52(2):145-7. PubMed ID: 23037633
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
    Bagadi S; Saikia T; Pany A; Das B
    Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circumventing resistance to kinase-inhibitor therapy.
    Druker BJ
    N Engl J Med; 2006 Jun; 354(24):2594-6. PubMed ID: 16775240
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
    Jabbour E; Kantarjian H; Cortes J
    Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
    Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
    Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
    Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
    Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
    [No Abstract]   [Full Text] [Related]  

  • 13. [Molecular targeting therapy for chronic myeloid leukemia].
    Kimura S
    Rinsho Ketsueki; 2007 Jan; 48(1):46-55. PubMed ID: 17313076
    [No Abstract]   [Full Text] [Related]  

  • 14. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
    Swords R; Alvarado Y; Cortes J; Giles FJ
    Curr Hematol Malig Rep; 2007 May; 2(2):83-8. PubMed ID: 20425355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
    Liu H; Chen XG
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):561-3. PubMed ID: 17236546
    [No Abstract]   [Full Text] [Related]  

  • 16. Kinase inhibitors in chronic myelogenous leukemia.
    Quintás-Cardama A; Cortes J
    Clin Adv Hematol Oncol; 2006 May; 4(5):365-74. PubMed ID: 16728945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors.
    Aoki J; Ohashi K; Kobayashi T; Kakihana K; Hirashima Y; Sakamaki H
    Leuk Lymphoma; 2012 Jul; 53(7):1412-4. PubMed ID: 22168276
    [No Abstract]   [Full Text] [Related]  

  • 19. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
    Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
    Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming kinase resistance in chronic myeloid leukemia.
    Lee F; Fandi A; Voi M
    Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.